- Guide to PHARMACOLOGY
Compound class: Synthetic organic
Comment: MMV253 is the preclinical candidate for the triaminopyrimidines (TAPs), a novel class of antimalarial compounds identified from a phenotypic screen .
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Guide to Malaria Pharmacology Comments|
|MMV253 is being developed as part of a single-exposure radical cure.
It is compound 13 in patent WO2015165660 .
Potential Target/Mechanism Of Action: Evidence from genetic experiments indicates that subunit D of Plasmodium V-type proton ATPase (PfV-type proton ATPase) may be a possible molecular target .
|Target Candidate Profiles|
|Profile||Intended Use||Target Stage||Comment||References|
|TCP-1||reduce parasite burden||asexual blood stages|